Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project.

Blackhall, Fiona H; Peters, S; Bubendorf, L; Dafni, U; Kerr, K; Hager, H; Soltermann, A; O'Byrne, K; Dooms, C; Sejda, A; Hernández-Losa, J; Marchetti, A; Savic, S; Tan, Q; Thunnissen, E; Speel, E; Cheney, R; Nonaka, Daisuke; de Jong, J; Martorell, M; Letovanec, I; Rosell, R; Stahel, R

Affiliation

Fiona H. Blackhall and Daisuke Nonaka, Manchester University and The Christie National Health Services Foundation Trust, Manchester

Issue Date

2014-07-28

Metadata

Show full item record

Abstract

The prevalence of anaplastic lymphoma kinase (ALK) gene fusion (ALK positivity) in early-stage non-small-cell lung cancer (NSCLC) varies by population examined and detection method used. The Lungscape ALK project was designed to address the prevalence and prognostic impact of ALK positivity in resected lung adenocarcinoma in a primarily European population.

Citation

Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project. 2014: J Clin Oncol

Journal

Journal of Clinical Oncology

URI

http://hdl.handle.net/10541/324239

DOI

10.1200/JCO.2013.54.5921

PubMed ID

25071109

Type

Article

Language

ISSN

1527-7755

Collections

All Christie Publications